Nicolas Leupin, M.D., Ph.D.

Nicolas Leupin is the Chief Medical Officer at Novocure, a position he has held since January 2024. In this role, he oversees medical affairs, medical safety, and clinical development operations. 

Before joining Novocure, Dr. Leupin served as the Chief Medical Officer at Molecular Partners, a clinical-stage biopharmaceutical company, where he led the development of multiple designed ankyrin repeat protein therapeutics. Prior to his time at Molecular Partners, Dr. Leupin served as the Chief Medical Officer at Argenx, a leader in the development of therapeutic antibodies, and was instrumental in the development of Vyvgart and other compounds. Before moving into executive leadership, Dr. Leupin held a number of clinical development leadership roles at Celgene in the myeloma and lymphoma programs. 

Dr. Leupin earned his M.D. at the University of Bern and his Ph.D. from the UBFC-Université in France. Dr. Leupin is a board certified medical oncologist with a specialty in hematological oncology. He has co-authored high-impact papers in peer-reviewed scientific journals, and is dedicated to educating the generation of oncologists through his continuing work as a lecturer of Tumor Biology at the University of Bern.